Passionflower for Health & Longevity - Quick Reference Sheet

Passionflower for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Passionflower is a dried plant preparation, sold as capsules, liquid extract and tea for nervous tension and poor sleep. Its clearest effect is a single dose before a stressful event: calming without next-day dullness, memory gaps or dependence. Sleep gains are modest, and benefit for long-standing anxiety is unsettled. It adds to anything else that sedates, and most tested supplements did not match their labels. (Full Review)

Protocol

Standard European dry-extract protocol
200–800 mg daily
Dry extract; or 0.5–2 g dried herb infused as tea up to three times daily. Most practitioners start at 250–400 mg.
Situational single-dose protocol
260–500 mg
Taken 30–90 minutes before an anticipated stressor; the regimen used in the surgical and dental trials.
Best time of day
Evening
Evening for the sleep and daily-calm goal, 30–90 minutes before the event for the situational goal. Daytime dosing is where sedation complaints concentrate.
Time to effect
Situational anxiety
30–90 minutes
Responds within 30–90 minutes of a single dose.
Sleep and daily calm
1–2 weeks
Measured at one to two weeks, with 30-day trials showing further gain; two weeks is the minimum useful trial period.
Sustained sedative dose reduction
12 months
Dose reduction sustained to 12 months when added to a supervised taper; the report is uncontrolled.

Benefits

Contraindications
  • Pregnant women at any gestational age, and women who are breastfeeding
  • Congenital long-QT syndrome, QTc above 470 ms, or a history of ventricular arrhythmia
  • Taking a monoamine oxidase inhibitor
  • Untreated moderate-to-severe obstructive sleep apnea (apnea-hypopnea index above 15 events per hour)
  • Decompensated liver disease (Child-Pugh Class C)
  • Prior hypersensitivity to Passiflora species or to other Passifloraceae
  • Within 48 hours of driving-critical or safety-critical duty without a prior personal response test
Key Interactions
  • Benzodiazepines and Z-drugs (diazepam, alprazolam, lorazepam, oxazepam, zolpidem, zaleplon, eszopiclone)
  • Opioids (oxycodone, morphine, tramadol, buprenorphine)
  • General anesthetics and pre-medication
  • Sedating over-the-counter medicines (diphenhydramine, doxylamine, chlorpheniramine)
  • Alcohol
  • Warfarin and antiplatelet agents
  • CYP3A4 substrates (simvastatin, atorvastatin, tacrolimus, ciclosporin, apixaban)
  • Sedative supplements (valerian, kava, hops, lemon balm, chamomile, melatonin, magnesium glycinate, L-Theanine, cannabidiol)
  • Antihypertensives and blood-pressure-lowering supplements

Risk & Side Effects

  • High: Drowsiness and daytime sedation
  • Medium: Potentiation of sedative and anti-anxiety drugs; substandard, misidentified or adulterated products
  • Low: Nausea, vomiting and dizziness at labeled doses; QT prolongation and non-sustained ventricular tachycardia; hypersensitivity vasculitis; adverse outcomes in pregnancy
  • Speculative: Reduced blood levels of CYP3A4-metabolized drugs

Monitoring

Marker Target Why
QTc interval Under 430 ms (men), under 440 ms (women) Screens the one serious cardiac signal reported
Serum potassium 4.2–4.6 mmol/L Low potassium lengthens repolarization independently
Serum magnesium (red blood cell) 5.0–6.5 mg/dL Low magnesium compounds any repolarization effect
ALT 10–26 U/L (men), 10–19 U/L (women) Confirms no unexpected liver effect from a multi-herb product
Insomnia Severity Index Under 8 The primary success measure for the sleep goal
GAD-7 anxiety score 4 or below The primary success measure for the anxiety goal
Sleep efficiency (time asleep as a share of time in bed, by wearable or diary) 88–92% Tracks the objective sleep endpoint that moved in trial

Cadence: Symptom scores at 2 weeks and 4 weeks, then every 3 months while use continues; the electrocardiogram is repeated only if the dose rises or a QT-prolonging drug is added, and liver enzymes are rechecked annually.

Qualitative Assessment

  • Morning grogginess in the first hour after waking — the earliest sign the dose is too high or too late
  • Daytime alertness and reaction quality, particularly during driving or training
  • Ease of falling asleep, as distinct from total sleep time
  • Subjective evenness of mood under a known stressor, rather than at rest
  • Absence of memory gaps around the evening dose